Key result
Systemic inflammation does not alter PFA-100 closure times, suggesting ASA platelet inhibition remains intact.
Why the study?
Inflammation may confound interpretation of platelet function results obtained with the PFA-100 system in patients treated with acetylsalicylic acid.
Does systemic inflammation influence PFA-100 closure times in PAOD patients treated with acetylsalicylic acid?
Observational (n=98)
Does systemic inflammation influence PFA-100 closure times in PAOD patients treated with acetylsalicylic acid?
Systemic inflammation does not appear to confound the interpretation of platelet function results measured by PFA-100 in PAOD patients on aspirin.
Supports reliable PFA-100 interpretation in ASA-treated PAOD patients despite inflammation; hypothesis-generating for other assays and outcomes.
Recently it was shown that inflammation adversely influences results obtained with the Platelet Function Analyzer System PFA-100, hypothesizing that inflammation could confound interpretation of platelet function results. We investigated the clinical relevance of these results in patients with peripheral arterial occlusive disease (PAOD), with and without signs of systemic inflammation. In 98 PAOD patients, all treated with acetylsalicylic acid (ASA), we measured PFA-100 closure times with the collagen-epinephrine test cartridges. C-reactive protein (CRP) values were measured as an indicator for systemic inflammation. Mean CRP levels were elevated in 23 patients (23%). There was no difference in mean PFA-100 results between patients with elevated CRP-levels and those without. During clinical use of the PFA system, systemic inflammation had no major influence on the performance of the collagen-epinephrine cartridge. With respect to the response to antiplatelet therapy with ASA, the results suggest that the platelet inhibitory effect of ASA is not reduced under inflammatory conditions.
No takes yet. Share an insight, caveat, or question.
Ziegler et al. (2005) conducted an observational in Peripheral arterial occlusive disease (PAOD) (n=98). Systemic inflammation (elevated CRP) vs. No systemic inflammation (normal CRP) was evaluated on PFA-100 closure times with collagen-epinephrine test cartridges. Systemic inflammation, present in 23% of patients, had no significant influence on PFA-100 closure times, suggesting ASA's platelet inhibitory effect is not reduced under inflammatory conditions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: